| Literature DB >> 28219437 |
Carlos Manuel Silva Martins1,2, Andreia Sofia da Costa Teixeira3, Luís Filipe Ribeiro de Azevedo4, Luísa Maria Barbosa Sá5, Paulo Alexandre Azevedo Pereira Santos5, Maria Luciana Gomes Domingues do Couto5, Altamiro Manuel Rodrigues da Costa Pereira4, Alberto Augusto Oliveira Pinto Hespanhol5, Cristina Maria Nogueira da Costa Santos4.
Abstract
BACKGROUND: The way software for electronic health records and laboratory tests ordering systems are designed may influence physicians' prescription. A randomised controlled trial was performed to measure the impact of a diagnostic and laboratory tests ordering system software modification.Entities:
Keywords: Decision making, computer-assisted; Decision support systems, clinical; Evidence-based practice; Preventive health services; Primary health care
Mesh:
Year: 2017 PMID: 28219437 PMCID: PMC5319139 DOI: 10.1186/s12911-017-0416-6
Source DB: PubMed Journal: BMC Med Inform Decis Mak ISSN: 1472-6947 Impact factor: 2.796
Fig. 1Usual ordering communication system: the basic shortcut menu
Fig. 2Modified ordering communication system: the basic shortcut menu. Red numbers: 1- Traffic lights coloured dots according to United States Preventive Services Task Force recommendations grades. 2- Text box with the summary of the recommendation for each selected test. 3-Link to the original recommendation at the USPSTF’s website. 4-Search for tests box, where any test, including those removed from the basic menu, can be searched and requested by typing the test’s name. 5- Legend of the coloured dots
United States Preventives Services Task Force (USPSTF) recommendations (March, 2012)
| Coloured dots | Gradea | Test | Summary of the recommendations |
|---|---|---|---|
| Red | D | Pelvic ultrasound | Not recommended as routine screening for ovarian cancer. |
| Red | D | Cancer antigen 19-9 | Not recommended as routine screening for pancreatic cancer. |
| Red | D | Rest electrocardiography | Not recommended in asymptomatic adults at low risk for coronary heart disease events. |
| Red | D | Exercise electrocardiography | Not recommended in asymptomatic adults at low risk for coronary heart disease events. |
| Red | D | Carotid artery ultrasound | Not recommended as screening for asymptomatic carotid artery stenosis in the general adult population. |
| Red | D | Spirometry | Not recommended as screening adults for chronic obstructive pulmonary disease. |
| Red | D | Hepatitis B surface antigen | Not recommended as routine screening. |
| Red | D | Hepatitis C antibodies | Not recommended as routine screening. |
| Yellow | I | Triglycerides | There is currently insufficient evidence of the benefit of including triglycerides as a part of the initial tests used to screen routinely for dyslipidemia. |
| Yellow | I | Prostate-specific antigen | The evidence is insufficient to recommend for or against routine screening for prostate cancer in men younger than 75. |
| Yellow | I | Lung computed tomography | The evidence is insufficient to recommend for or against routine screening for lung cancer. |
| Yellow | I | Lung X-ray | The evidence is insufficient to recommend for or against routine screening for lung cancer. |
| Yellow | I | Thyroid-stimulating hormone | The evidence is insufficient to recommend for or against routine screening. |
| Green | B | Glucose | Screening for type 2 diabetes recommended in asymptomatic adults with sustained blood pressure (either treated or untreated) greater than 135/80 mm Hg. |
| Green | A/B | Total cholesterol | Recommended every 5 years, for men aged 35 and older and women 45 and older if they are at increased risk for coronary heart disease. At younger ages if they are at increased risk for coronary heart disease. |
| Green | B | Mammography | Biennial screening recommended for women aged 50 to 74 years. |
| Green | A | Cervicovaginal cytology | Every 3 years screening recommended for women who have cervix, 21 to 65 years old. |
| Green | A | Faecal occult blood test | Recommended annually as a possible method of screening for colorectal cancer, 50 to 75 years. |
| Green | A | Colonoscopy | Recommended every 10 years as a possible method of screening for colorectal cancer, 50 to 75 years. |
| Green | A | Flexible sigmoidoscopy | Recommended every 5 years as a possible method of screening for colorectal cancer, 50 to 75 years. |
| Green | A/B | HDL cholesterol | Recommended every 5 years, for men aged 35 and older and women 45 and older if they are at increased risk for coronary heart disease. At younger ages if they are at increased risk for coronary heart disease. |
| Green | B | DXAb of the hip and lumbar spine | Screening recommended for osteoporosis in women aged 65 years or older and in younger women whose fracture risk is equal to or greater than that of a 65-year-old. |
| Green | A | Venereal Disease Research Laboratory | Recommended for persons at increased risk for syphilis infection. |
aUSPSTF grades A and B: the USPSTF recommends the service, marked with green dots. Grade D: the USPSTF recommends against the service, marked with red dots. Grade I: the USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of the service, marked with yellow dots
b DXA Dual-energy X-ray absorptiometry
Fig. 3Flowchart summary of the trial
Baseline data ranges for each group based on the last 6 months before the electronic health record (EHR) software modification
| Usual software (control group) | Modified software (intervention group) | |
|---|---|---|
| Family physicians | 57–61 | 55–63 |
| Total of patients covered by Health Centers | 110,781–110,783 | 79,847–79,850 |
| Face to face consultations | 10,725–13,493 | 10,047–12,598 |
Pre-post comparison of the monthly number of diagnostic and lab tests prescribed per 100 consultations (time series analysis, ARIMA model)
| Control group | Intervention group | |||||
|---|---|---|---|---|---|---|
| (always exposed to usual EHR software) | ||||||
| Before | After |
| Before software modification | After software modification |
| |
| Diagnostic and lab tests that were withdrawn from the basic menu | ||||||
| Uric acid | 12 | 10.9 | 0.094 | 11.2 | 4.5 | <0.001 |
| Serum protein electrophoresis | 4.1 | 3.2 | 0.001 | 4.7 | 0.6 | <0.001 |
| Sedimentation rate | 8.3 | 7.7 | 0.259 | 7.1 | 2 | <0.001 |
| Rest electrocardiographya | 7.7 | 6.8 | 0.189 | 6.4 | 5.4 | 0.072 |
| Lung X-ray | 1.7 | 1.6 | 0.351 | 1.9 | 1.4 | 0.002 |
| All tests withdrawn | 33.8 | 30.3 | 0.075 | 31.3 | 13.9 | <0.001 |
| Diagnostic and laboratory tests that were added to the basic menu | ||||||
| HDL cholesterolb | 19 | 17.8 | 0.357 | 16.7 | 16 | 0.566 |
| Triglycerides | 19.6 | 18.3 | 0.349 | 17.4 | 16.2 | 0.372 |
| Faecal occult blood testb | 8.5 | 7.3 | 0.236 | 4.9 | 6.3 | 0.017 |
| Cervicovaginal cytologyb | 4.8 | 4.7 | 0.779 | 4.5 | 4.4 | 0.905 |
| Mammographyb | 1.9 | 1.8 | 0.332 | 1.6 | 1.7 | 0.631 |
| All tests added | 53.7 | 49.9 | 0.334 | 45 | 44.7 | 0.909 |
| Diagnostic and laboratory tests that were marked with green dots (USPSTF grade A and B) | ||||||
| Glucose | 22.7 | 21.5 | 0.402 | 20.4 | 18.8 | 0.199 |
| Total cholesterol | 20.6 | 19.3 | 0.345 | 18.3 | 16.9 | 0.264 |
| Colonoscopy | 1.4 | 1.5 | 0.325 | 1.2 | 1.2 | 0.940 |
| Flexible sigmoidoscopy | 0.1 | 0.1 | 0.031 | 0.1 | 0.1 | 0.115 |
| DXAα | 1 | 0.7 | 0.035 | 0.6 | 0.6 | 0.562 |
| VDRLβ | 2.1 | 2 | 0.234 | 1.9 | 1.6 | 0.003 |
| All green marked | 82.1 | 76.7 | 0.331 | 70.2 | 67.5 | 0.560 |
| Diagnostic and laboratory tests that were marked with red dots (USPSTF grade D) | ||||||
| Pelvic ultrasound | 1.2 | 1.1 | 0.033 | 1 | 1.1 | 0.815 |
| Cancer antigen 19-9 | 0.2 | 0.2 | 0.911 | 0.1 | 0.1 | 0.013 |
| Exercise electrocardiography | 0.5 | 0.6 | 0.308 | 0.5 | 0.4 | 0.113 |
| Carotid artery ultrasound | 0.3 | 0.2 | 0.484 | 0.2 | 0.2 | 0.072 |
| Spirometry | 0.5 | 0.5 | 0.959 | 0.3 | 0.5 | 0.010 |
| Hepatitis B surface antigen | 1.6 | 1.7 | 0.627 | 1.3 | 1.2 | 0.147 |
| Hepatitis C antibodies | 1.2 | 1.2 | 0.379 | 0.9 | 0.9 | 0.898 |
| All red marked | 13.1 | 12.3 | 0.341 | 10.9 | 9.7 | 0.102 |
aTests that were also marked with red dots. bTests that were also marked with green dots
α- DXA: Dual-energy X-ray absorptiometry β-VDRL: Venereal Disease Research Laboratory
Comparison of the monthly number of diagnostic and lab tests prescribed per 100 consultations between control and intervention groups, before and after EHR software modification (independent sample t test with Bonferroni correction)
| Before (always exposed to usual EHR software) | After software modification (first month, washout period, excluded) | |||||||
|---|---|---|---|---|---|---|---|---|
| Control | Intervention |
| Cohen’s d | Control | Intervention |
| Cohen’s d | |
| Diagnostic and lab tests that were withdrawn from the basic menu | ||||||||
| Uric acid | 12.0 | 11.2 | 1.000 | 0.632 | 10.5 | 4.6 | <0.001 | 6.138 |
| Serum protein electrophoresis | 4.1 | 4.7 | 0.605 | −1.039 | 3.2 | 0.6 | <0.001 | 7.384 |
| Sedimentation rate | 8.3 | 7.1 | 0.315 | 1.207 | 7.5 | 2.0 | <0.001 | 10.818 |
| Rest electrocardiographya | 7.7 | 6.4 | 0.465 | 1.073 | 6.6 | 5.4 | 0.070 | 1.544 |
| Lung X-ray | 1.7 | 1.9 | 0.985 | −0.802 | 1.5 | 1.4 | 1.000 | 0.441 |
| All tests withdrawn | 33.8 | 31.3 | 0.292 | 0.641 | 29.29 | 14.01 | <0.001 | 7.174 |
| Diagnostic and laboratory tests that were added to the basic menu | ||||||||
| HDL cholesterolb | 19 | 16.7 | 0.640 | 0.958 | 17.2 | 15.9 | 1.000 | 0.702 |
| Triglycerides | 19.6 | 17.4 | 0.830 | 0.862 | 17.7 | 16.1 | 0.640 | 0.874 |
| Faecal occult blood testb | 8.5 | 4.9 | 0.015 | 2.207 | 6.9 | 6.2 | 0.425 | 1.003 |
| Cervicovaginal cytologyb | 4.8 | 4.5 | 1.000 | 0.468 | 4.5 | 4.4 | 1.000 | 0.361 |
| Mammographyb | 1.9 | 1.6 | 0.855 | 0.851 | 1.7 | 1.7 | 1.000 | 0.157 |
| All tests added | 53.7 | 45.0 | 0.070 | 1.172 | 48.0 | 44.3 | 0.158 | 0.805 |
| Diagnostic and laboratory tests that were marked with green dots (USPSTF grade A and B) | ||||||||
| Glucose | 22.7 | 20.4 | 0.864 | 0.914 | 20.9 | 18.6 | 0.228 | 1.246 |
| Total cholesterol | 20.6 | 18.3 | 0.930 | 0.885 | 18.7 | 16.8 | 0.450 | 1.040 |
| Colonoscopy | 1.4 | 1.2 | 0.042 | 1.943 | 1.5 | 1.1 | 0.006 | 2.345 |
| Flexible sigmoidoscopy | 0.12 | 0.07 | <0.001 | 3.002 | 0.05 | 0.08 | 0.186 | −1.326 |
| DEXA | 1.0 | 0.6 | 0.036 | 2.010 | 0.7 | 0.5 | 0.414 | 1.063 |
| VDRL | 2.1 | 1.9 | 0.552 | 1.077 | 1.9 | 1.6 | 0.102 | 1.483 |
| All green marked | 82.1 | 70.2 | 0.070 | 1.170 | 74.1 | 66.8 | 0.070 | 1.064 |
| Diagnostic and laboratory tests that were marked with red dots (USPSTF grade D) | ||||||||
| Pelvic ultrasound | 1.20 | 1.04 | 0.084 | 1.774 | 1.02 | 1.08 | 1.000 | −0.305 |
| Cancer antigen 19-9 | 0.18 | 0.13 | 0.616 | 1.093 | 0.17 | 0.08 | <0.001 | 2.513 |
| Exercise electrocardiography | 0.52 | 0.48 | 1.000 | 0.416 | 0.56 | 0.38 | 0.028 | 1.900 |
| Carotid artery ultrasound | 0.27 | 0.23 | 1.000 | 0.750 | 0.25 | 0.15 | 0.021 | 1.978 |
| Spirometry | 0.47 | 0.34 | 0.021 | 2.307 | 0.45 | 0.52 | 0.812 | −0.902 |
| Hepatitis B surface antigen | 1.60 | 1.34 | 0.084 | 1.756 | 1.59 | 1.24 | 0.028 | 1.925 |
| Hepatitis C antibodies | 1.15 | 0.91 | 0.021 | 2.207 | 1.18 | 0.91 | 0.014 | 2.045 |
| All red marked | 13.1 | 10.9 | 0.021 | 1.583 | 11.8 | 9.8 | 0.003 | 1.941 |
aTests that were also marked with red dots. bTests that were also marked with green dots
α- DXA Dual-energy X-ray absorptiometry, β-VDRL Venereal Disease Research Laboratory